Redoing surgical mitral valve replacement (SMVR) or undergoing transcatheter mitral valve replacement (TMVR) in patients with failed prostheses results in similar 3-year outcomes, reports a recent study. TMVR, however, initially displays a lower risk of major adverse cardiovascular events (MACE), but this risk increases after 6 months.